Pages that link to "Q59751499"

The following pages link to Scott M. Wasserman (Q59751499):

Displaying 7 items.

• The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. (Q34209536) (← links)
• Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document (Q38115936) (← links)
• Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study (Q39174869) (← links)
• Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial (Q50602023) (← links)
• Corrigendum to ‘Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial’ [Eur J Heart Fail2009;11:795-801] (Q57396245) (← links)
• The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure (Q57422687) (← links)
• Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia (Q57422720) (← links)